1
|
Hoffmann D, Buchberger B, Nemetz C. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling. J Clin Virol 2005; 32:294-9. [PMID: 15780808 DOI: 10.1016/j.jcv.2004.09.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2004] [Revised: 09/03/2004] [Accepted: 09/08/2004] [Indexed: 11/29/2022]
Abstract
BACKGROUND Given the expanding antiretroviral therapy, inexpensive and fast HIV drug resistance assays are urgently needed. In this view, we have developed a novel phenotypic resistance test for HIV-1 protease inhibitors (PIs) based on recombinant expression of patient-derived HIV PR in Escherichia coli and subsequent enzymatic testing in a fluorescent readout. OBJECTIVES To facilitate and expedite the test procedure, we have introduced coupled in vitro transcription/translation using a commercially available technology called RTS for producing enzymatically active HIV-1 protease (PR). STUDY DESIGN We expressed one wild type PR and one highly resistant mutant starting from molecular clones as well as three patient-derived PRs. The amplified PR gene was either ligated into an expression vector or directly used as a template for the in vitro transcription/translation reaction. Enzymatic susceptibility data derived from in vitro expressed PRs were correlated to the respective results from E. coli expression and genotypic evaluation. RESULTS All tested enzymes were obtained in sufficient quantities for complete resistance profiling to five PIs. The PRs required no purification prior to the enzymatic assay. Inhibition constants and enzymatic resistance factors compared well to corresponding data from PRs expressed in parallel in E. coli. Enzymatic resistance was in good agreement with the respective PR genotype. CONCLUSION The presented in vitro transcription/translation system represents a novel approach for HIV PR expression starting from molecular clones or patient samples. Coupled with the enzyme-kinetic PR assay recently developed in our group it allows to sensitively quantify resistance to PIs. The test system is significantly less laborious and faster than currently available phenotypic drug resistance assays.
Collapse
Affiliation(s)
- Dieter Hoffmann
- Department of Virology, Max von Pettenkofer-Institute, University of Munich, Pettenkoferstr. 9a, D-80336 Munich, Germany
| | | | | |
Collapse
|
2
|
Hoffmann D, Assfalg-Machleidt I, Nitschko H, von der Helm K, Koszinowski U, Machleidt W. Rapid enzymatic test for phenotypic HIV protease drug resistance. Biol Chem 2003; 384:1109-17. [PMID: 12956428 DOI: 10.1515/bc.2003.124] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
A phenotypic resistance test based on recombinant expression of the active HIV protease in E. coli from patient blood samples was developed. The protease is purified in a rapid one-step procedure as active enzyme and tested for inhibition by five selected synthetic inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) used presently for chemotherapy of HIV-infected patients. The HPLC system used in a previous approach was replaced by a continuous fluorogenic assay suitable for high-throughput screening on microtiter plates. This reduces significantly the total assay time and allows the determination of inhibition constants (Ki). The Michaelis constant (Km) and the inhibition constant (Ki) of recombinant wild-type protease agree well with published data for cloned HIV protease. The enzymatic test was evaluated with recombinant HIV protease derived from eight HIV-positive patients scored from 'sensitive' to 'highly resistant' according to mutations detected by genotypic analysis. The measured Ki values correlate well with the genotypic resistance scores, but allow a higher degree of differentiation. The non-infectious assay enables a more rapid yet sensitive detection of HIV protease resistance than other phenotypic assays.
Collapse
Affiliation(s)
- Dieter Hoffmann
- Max von Pettenkofer-Institut, Abteilung für Virologie der Ludwig-Maximilians-Universität, Pettenkoferstr. 9a, D-80336 München, Germany
| | | | | | | | | | | |
Collapse
|
3
|
Gehringer H, Von der Helm K, Seelmeir S, Weissbrich B, Eberle J, Nitschko H. Development and evaluation of a phenotypic assay monitoring resistance formation to protease inhibitors in HIV-1-infected patients. J Virol Methods 2003; 109:143-52. [PMID: 12711057 DOI: 10.1016/s0166-0934(03)00065-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A novel phenotypic assay, based on recombinant expression of the HIV-1-protease was developed and evaluated; it monitors the formation of resistance to protease inhibitors. The HIV-1 protease-encoding region from the blood sample of patients was amplified, ligated into the expression vector pBD2, and recombinantly expressed in Escherichia coli TG1 cells. The resulting recombinant enzyme was purified by a newly developed one-step acid extraction protocol. The protease activity was determined in presence of five selected HIV protease inhibitors and the 50% inhibitory concentration (IC(50)) to the respective protease inhibitors determined. The degree of resistance was expressed in terms of x-fold increase in IC(50) compared to the IC(50) value of an HIV-1 wild type protease preparation. The established test system showed a reproducible recombinant expression of each individual patients' HIV-1 protease population. Samples of nine clinically well characterised HIV-1-infected patients with varying degrees of resistance were analysed. There was a good correlation between clinical parameters and the results obtained by this phenotypic assay. For the majority of patients a blind genotypic analysis of the patients' protease domain revealed a fair correlation to the results of the phenotypic assay. In a minority of patients our phenotypic results diverged from the genotypic ones. This novel phenotypic assay can be carried out within 8-10 days, and offers a significant advantage in time to the current employed phenotypic tests.
Collapse
Affiliation(s)
- Heike Gehringer
- Department of Virology, Max von Pettenkofer-Institute, Ludwig-Maximilians-University (LMU), Pettenkoferstr. 9a, D-80336 Munich, Germany
| | | | | | | | | | | |
Collapse
|
4
|
Vandamme AM, Houyez F, Bànhegyi D, Clotet B, De Schrijver G, De Smet KAL, Hall WW, Harrigan R, Hellmann N, Hertogs K, Holtzer C, Larder B, Pillay D, Race E, Schmit JC, Schuurman R, Shulse E, Sönnerborg A, Miller V. Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up. Antivir Ther 2001. [DOI: 10.1177/135965350100600103] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
HIV drug resistance is one of the major limitations in the successful treatment of HIV-infected patients using currently available antiretroviral combination therapies. When appropriate, drug susceptibility profiles should be taken into consideration in the choice of a specific combination therapy. Guidelines recommending resistance testing in certain circumstances have been issued. Many clinicians have access to resistance testing and will increasingly use these results in their treatment decisions. In this document, we comment on the different methods available, and the relevant issues relating to the clinical application of these tests. Specifically, the following recommendations can be made: (i) genotypic and phenotypic HIV-1 drug resistance analyses can yield complementary information for the clinician. However, insufficient information currently exists as to which approach is preferable in any particular clinical setting; (ii) when HIV-1 drug resistance testing is required, it is recommended that testing be performed on plasma samples obtained before starting, stopping or changing therapy, on samples that have a viral load above the detection limit of the resistance test; (iii) the panel recommends that genotypic and phenotypic HIV-1 drug resistance testing for clinical purposes be performed in a certified laboratory under strict quality control and quality assurance standards; and (iv) the panel recommends that resistance testing laboratories provide clinicians with resistance reports that include a list of drug-related resistance mutations (genotype) and/or a list of drug-related fold resistance values (phenotype), with interpretations of each by an experienced virologist. The interpretation of genotypic and phenotypic analysis is a complex and developing science, and in order to understand HIV-1 drug resistance reports, communication between the requesting clinician and the expert that interpreted the resistance report is recommended.
Collapse
Affiliation(s)
- A-M Vandamme
- AIDS Reference Laboratory, Rega Institute and University Hospitals, KU Leuven, Leuven, Belgium
| | | | | | - B Clotet
- Fundacio IRSI-Caixa, Badalona, Spain
| | | | | | - WW Hall
- Virus Reference Laboratory, University College, Dublin, Ireland
| | - R Harrigan
- BC Center for Excellence in HIV/AIDS, Vancouver, Canada (currently at Virco, UK)
| | | | - K Hertogs
- Virco, Mechelen, Belgium and Virco, UK
| | | | - B Larder
- Virco, Mechelen, Belgium and Virco, UK
| | - D Pillay
- PHLS Antiviral Susceptibility Reference Unit, University of Birmingham Medical School, UK
| | - E Race
- Hôpital Bichat-Claude Bernard, France (currently at VIRalliance, France)
| | - J-C Schmit
- Centre Hospitalier de Luxembourg, Luxembourg
| | - R Schuurman
- Eijkman-Winkler Institute, Utrecht University, Utrecht, The Netherlands
| | - E Shulse
- Applied Biosystems, Foster City, Calif., USA
| | | | - V Miller
- Klinikum der JW Goethe Universität, Frankfurt, Germany
| |
Collapse
|
5
|
Vandamme AM, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 1999; 57:337-61. [PMID: 10193687 DOI: 10.2165/00003495-199957030-00006] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Current recommendations for the treatment of HIV-infected patients advise highly active antiretroviral therapy (HAART) consisting of combinations of 3 or more drugs to provide long-term clinical benefit. This is because only a complete suppression of virus replication will be able to prevent virus drug resistance, the main cause of drug failure. Virus drug resistance may remain a cause of concern in patients who have already received suboptimal mono- or bitherapy, or for patients who do not experience complete shut-down of virus replication under HAART. For these patients, replacement of one combination therapy regimen by another at drug failure, taking into account the existing resistance profile, will be needed. The development of new drugs will remain necessary for those patients who have failed to respond to all currently available drugs, as will be the institution of more effective and less toxic HAART regimens.
Collapse
Affiliation(s)
- A M Vandamme
- Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Belgium.
| | | | | |
Collapse
|
6
|
Vandamme AM, Van Vaerenbergh K, De Clercq E. Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 1998; 9:187-203. [PMID: 9875399 DOI: 10.1177/095632029800900301] [Citation(s) in RCA: 100] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
It is now generally accepted that mono- and bitherapy for human immunodeficiency virus type 1 (HIV-1) infection are only transiently efficient mainly due to virus drug resistance. To obtain a sustained benefit from antiviral therapy, current guidelines recommend at least triple-drug combinations, or the so-called highly active antiretroviral therapy (HAART). In some patients, HAART can be problematic, either because it is difficult to remain compliant or because previous suboptimum therapies have limited the choice of drugs. For compliant drug-naive patients, HAART should be able to offer long-term virus suppression, when changing from first- to second- to third-line HAART at drug failure. Long-term treatment might ultimately result in multi-drug resistant virus leaving few options for salvage therapy. HIV drug resistance testing to guide this salvage therapy and the development of new drugs to allow new options will therefore remain priorities in anti-HIV drug research.
Collapse
Affiliation(s)
- A M Vandamme
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
| | | | | |
Collapse
|
7
|
Ding YS, Owen SM, Lal RB, Ikeda RA. Efficient expression and rapid purification of human T-cell leukemia virus type 1 protease. J Virol 1998; 72:3383-6. [PMID: 9525666 PMCID: PMC109825 DOI: 10.1128/jvi.72.4.3383-3386.1998] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Human T-cell leukemia virus type 1 (HTLV-1) is an oncovirus that is clinically associated with adult T-cell leukemia. We report here the construction of a pET19-based expression clone containing HTLV-1 protease fused to a decahistidine-containing leader peptide. The recombinant protein is efficiently expressed in Escherichia coli, and the fusion protein can be easily purified by affinity chromatography. Active mature protease in yields in excess of 3 mg/liter of culture can then be obtained by a novel two-step refolding and autoprocessing procedure. The purified enzyme exhibited Km and Kcat, values of 0.3 mM and 0.143 sec(-1) at pH 5.3 and was inhibited by pepstatin A.
Collapse
Affiliation(s)
- Y S Ding
- School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta 30332-0400, USA
| | | | | | | |
Collapse
|